• Users Online: 960
  • Print this page
  • Email this page
REVIEW FOR THE SHEIKH HAMDAN BIN RASHID AL MAKTOUM AWARD FOR MEDICAL SCIENCES
Year : 2014  |  Volume : 7  |  Issue : 3  |  Page : 367-373

The evolution of targeted therapy of the erbB2/neu oncoprotein for human cancer therapy


Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Correspondence Address:
Mark I Greene
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7707/hmj.351

Rights and Permissions

The recognition that the erbB2/neu oncogene encodes a cell-surface receptor led to the development of targeted therapy. The erbB2/neu oncogene was found to encode a tyrosine kinase receptor that can form active dimers as a consequence of mutation or amplification. The receptor protein p185erbB2/neu was found to be able to dimerize with itself or with other members of the erbB family to create heteromers with active enzymatic activity and to diversify signalling and transforming patterns. When mutated or amplified, these homodimeric or heterodimeric kinases lead to human cancers, including breast and stomach malignancies. The first targeted therapeutics were monoclonal antibodies that were directed at the ectodomain of the p185erbB2/neu protein and resulted in receptor down-modulation and kinase inhibition. Unexpectedly, disabling the erbB2/neu kinase complex caused the malignant cells to convert to a more normal phenotype. The first demonstration that malignant properties could be reversed challenged all thinking at the time that malignant transformation could progressively lead to more phenotypically abnormal cells. Subsequent to phenotypical reversion, the tumour cells become sensitive to extrinsic death signals from radiation and chemotherapy. The disabling of oncoproteins that determine malignancy is an approach that is now a standard therapy for human cancer.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed189    
    Printed10    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal